I-Mab Newsroom

H.C. Wainwright Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $8

Moomoo NewsNov 15 07:33 ET

I-MAB Receives Buy Rating as Uliledlimab and Givastomig Show Promising Clinical Progress

TipRanksNov 15 06:37 ET

I-MAB Analyst Ratings

BenzingaNov 15 06:31 ET

H.C. Wainwright Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $8

Moomoo NewsSep 18 08:31 ET

Analysts Are Bullish on These Healthcare Stocks: Clene (CLNN), I-MAB (IMAB)

TipRanksSep 18 08:22 ET

I-MAB Analyst Ratings

BenzingaAug 29 07:54 ET

I-MAB Buy Rating Justified by Strong Leadership and Promising Pipeline

TipRanksApr 12 06:10 ET

I-MAB Analyst Ratings

BenzingaApr 12 06:07 ET

I-MAB Analyst Ratings

BenzingaMar 18 06:42 ET

Analysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)

TipRanksMar 18 06:25 ET

I-MAB Analyst Ratings

BenzingaMar 15 09:31 ET

I-MAB Buy Rating: Strategic Pivot to U.S. Market and Promising Pipeline

TipRanksFeb 12 08:18 ET

I-MAB Analyst Ratings

BenzingaFeb 8 15:10 ET

Analysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)

TipRanksFeb 8 15:10 ET

Needham Maintains Buy on I-MAB, Lowers Price Target to $23

BenzingaSep 25, 2023 05:57 ET

I-MAB Analyst Ratings

BenzingaSep 25, 2023 05:55 ET

Cantor Fitzgerald Reiterates Overweight on I-MAB, Maintains $25 Price Target

BenzingaSep 5, 2023 09:59 ET

I-MAB Analyst Ratings

BenzingaSep 5, 2023 09:58 ET

I-MAB Analyst Ratings

BenzingaAug 18, 2023 10:43 ET

I-MAB (IMAB) Gets a Buy From H.C. Wainwright

TipRanksAug 18, 2023 08:05 ET